Toxicological Research

Korean Society of Toxicology & Korea Environmental Mutagen Society (한국독성학회)
권호 표지
DOI QR코드

DOI QR Code

Phosphodiesterase 11 A (PDE11A), a potential biomarker for glioblastoma

  • Lee, Hyunji (Department of Pharmacology, College of Medicine, Chungnam National University) ;
  • Park, Sungjin (Department of Pharmacology, College of Medicine, Chungnam National University) ;
  • Kong, Gyeyeong (Department of Pharmacology, College of Medicine, Chungnam National University) ;
  • Kwon, So Hee (College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University) ;
  • Park, Jisoo (Department of Pharmacology, College of Medicine, Chungnam National University) ;
  • Park, Jongsun (Department of Pharmacology, College of Medicine, Chungnam National University) ;
  • Kim, Seon‑Hwan (Department of Neurosurgery, Institute for Cancer Research, College of Medicine, Chungnam National University)
  • Received : 2021.11.26
  • Accepted : 2022.03.10
  • Published : 2022.07.15
⟨ Previous Next ⟩

Abstract

Phosphodiesterase 11A (PDE11A), a 3',5'-cyclic nucleotide phosphodiesterase, is a key regulator of intracellular signaling that functions by degrading cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). However, the function of PDE11A in brain tumors is currently unclear. In this study, we found that PDE11A may be involved in glioblastoma development. The protein and mRNA levels of PDE11A were significantly higher in U87-MG, U251-MG and U343-MG glioblastoma cell lines. Gene expression analyses by deep-sequencing revealed that PDE11A mRNA levels were higher in U87-MG and U251-MG cells compared to other cells in the cerebral cortex. A comprehensive analysis of The Cancer Genome Atlas (TCGA) data revealed that PDE11A expression was also elevated in glioblastoma patients. Taken together, these data indicate that PDE11A expression was increased in glioblastoma cell lines and glioma patients, suggesting that PDE11A could be a putative diagnostic marker and therapeutic target for glioma.

Keywords

Acknowledgement

This work was financially supported by a research fund from Chungnam National University (grant to SH Kim) and by the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MEST) (NRF-2021R1A2C1008492, NRF-2020R1F1A1049801, NRF-2021R1C1C200845611). The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see: http://www.textcheck.com/certificate/cNOwdf.

References

  1. Louis DN et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803-820. https://doi.org/10.1007/s00401-016-1545-1
  2. Glaser T et al (2017) Targeted nanotechnology in glioblastoma multiforme. Front Pharmacol. https://doi.org/10.3389/fphar.2017.00166
  3. Virk SM et al (2015) Identification of variants in primary and recurrent glioblastoma using a cancer-specific gene panel and whole exome sequencing. PLoS One. https://doi.org/10.1371/journal.pone.0124178
  4. Singh SK et al (2004) Identification of human brain tumour initiating cells. Nature 432:396-401. https://doi.org/10.1038/nature03128
  5. Singh SK et al (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821-5828. (PMID: 14522905)
  6. Brennan CW et al (2013) The somatic genomic landscape of glioblastoma. Cell 155:462-477. https://doi.org/10.1016/j.cell.2013.09.034
  7. Kelly MP (2015) Does phosphodiesterase 11A (PDE11A) hold promise as a future therapeutic target? Curr Pharm Des 21:389-416. https://doi.org/10.2174/1381612820666140826114941
  8. Hannah-Shmouni F, Faucz FR, Stratakis CA (2016) Alterations of phosphodiesterases in adrenocortical tumors. Front Endocrinol. https://doi.org/10.3389/fendo.2016.00111
  9. Conti M et al (2003) Cyclic AMP-specifc PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 278:5493-5496. https://doi.org/10.1074/jbc.R200029200
  10. Giembycz MA (2002) Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far. Monaldi Arch Chest Dis 57:48-64. (PMID: 12174704)
  11. Ahmed WS, Geethakumari AM, Biswas KH (2021) Phosphodiesterase 5 (PDE5): structure-function regulation and therapeutic applications of inhibitors. Biomed Pharmacother 134:111128. https://doi.org/10.1016/j.biopha.2020.111128
  12. Kim HB, Yoo BS (2016) Propolis inhibits UVA-induced apoptosis of human keratinocyte HaCaT cells by scavenging ROS. Toxicol Res 32:345-351. https://doi.org/10.5487/TR.2016.32.4.345
  13. Li Y et al (2013) PKB-mediated PHF20 phosphorylation on Ser291 is required for p53 function in DNA damage. Cell Signal 25:74-84. https://doi.org/10.1016/j.cellsig.2012.09.009
  14. Na CH et al (2015) Identification of protein markers specific for papillary renal cell carcinoma using imaging mass spectrometry. Mol Cells 38:624-629. https://doi.org/10.14348/molcells.2015.0013
  15. Demeure K et al (2016) Targeted proteomics to assess the response to anti-angiogenic treatment in human glioblastoma (GBM). Mol Cell Proteomics 15:481-492. https://doi.org/10.1074/mcp.M115.052423
  16. Kim JE, Lim M (2015) The role of checkpoints in the treatment of GBM. J Neurooncol 123:413-423. https://doi.org/10.1007/s11060-015-1747-8
  17. Hathout L, Patel V (2016) Estimating subthreshold tumor on MRI using a 3D-DTI growth model for GBM: an adjunct to radiation therapy planning. Oncol Rep 36:696-704. https://doi.org/10.3892/or.2016.4878
  18. Carney JA et al (2010) Familial micronodular adrenocortical disease, Cushing syndrome, and mutations of the gene encoding phosphodiesterase 11A4 (PDE11A). Am J Surg Pathol 34:547-555. https://doi.org/10.1097/PAS.0b013e3181d31f49
  19. Koch L (2011) Cancer: PDE11a-a phenotype modifier in carney complex. Nat Rev Endocrinol 7:64. https://doi.org/10.1038/ nrendo.2010.225
  20. Faucz FR et al (2011) Phosphodiesterase 11A (PDE11A) genetic variants may increase susceptibility to prostatic cancer. J Clin Endocrinol Metab 96:E135-E140. https://doi.org/10.1210/jc.2010-1655